Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
The company will imminently start its third pivotal trial of PF-08634404.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The company ditches lorigerlimab in prostate cancer.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
The response rate jumps to 30% with higher doses of IMA402.
